KRAS and non-small cell lung carcinoma: The SMARCA4/KRAS-co-mutated patients had significantly shorter PFS (1.4 versus 4.1 months, HR: 0.25; p < 0.001) and OS (3 versus 15.1 months, HR: 0.29; p < 0.001) compared with NSCLC patients with SMARCA4 WT/KRAS mutations (N = 159).